What this medicine is used for

(ARTG)

MELANOMA,OPDIVO SC, as monotherapy, is indicated for the adjuvant treatment of adult patients with completely resected Stage IIB, IIC, III or IV melanoma.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic melanoma.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic melanoma following treatment with intravenous OPDIVO and ipilimumab combination therapy. The approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. All analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,NON-SMALL CELL LUNG CANCER (NSCLC),OPDIVO SC, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer (NSCLC).,OPDIVO SC, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumours equal to or greater than 4cm or node positive) non-small cell lung cancer and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO SC as a single agent in the adjuvant setting after surgical resection.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after prior chemotherapy.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with progression on or after prior chemotherapy. In patients with tumour EGFR or ALK genomic aberrations, OPDIVO SC should be used after progression on or after targeted therapy.,RENAL CELL CARCINOMA (RCC),OPDIVO SC, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma following combination treatment with intravenous OPDIVO and ipilimumab.,OPDIVO SC, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with advanced clear cell renal cell carcinoma after prior anti-angiogenic therapy.,SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),OPDIVO SC, as monotherapy, is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adult patients progressing on or after platinum based therapy.,UROTHELIAL CARCINOMA (UC),OPDIVO SC, as monotherapy, is indicated for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) who are at high risk of recurrence after undergoing radical resection of MIUC.,OPDIVO SC, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma after prior platinum-containing therapy. The approval of this indication is based on objective response rate and duration of response in a single arm study.,HEPATOCELLULAR CARCINOMA (HCC),OPDIVO SC, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma following combination treatment with intravenous OPDIVO and ipilimumab.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with hepatocellular carcinoma after prior sorafenib therapy. This indication is approved based on objective response rate and duration of response in a single arm study. An improvement in survival or disease-related symptoms has not been established.,OESOPHAGEAL SQUAMOUS CELL CARCINOMA (OSCC),OPDIVO SC, in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression equal to or greater than 1% as determined by a validated test.,OPDIVO SC, as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum based chemotherapy.,ADJUVANT OESOPHAGEAL CANCER (OC) OR GASTRO-OESOPHAGEAL JUNCTION CANCER (GOJC),OPDIVO SC, as monotherapy, is indicated for the adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer in adult patients who have received neoadjuvant chemoradiotherapy.,GASTRIC CANCER (GC), GASTRO-OESOPHAGEAL JUNCTION CANCER (GOJC), OR OESOPHAGEAL ADENOCARCINOMA (OAC),OPDIVO SC, in combination with fluoropyrimidine- and platinum-based combination chemotherapy, is indicated for the first-line treatment of adult patients with HER2 negative advanced or metastatic gastric or gastro-oesophageal junction or oesophageal adenocarcinoma.,MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC),OPDIVO SC, as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic colorectal cancer (CRC) that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) as determined by a validated test following combination treatment with intravenous OPDIVO and ipilimumab.

How to use this medicine

(ARTG)

This medicine contains one component only.

Storage conditions

(ARTG)

• Store at 2 to 8 degrees Celsius
• Protect from Light
• Do not Freeze
• Refrigerate
• Do not Shake
• Shelf lifetime is 18 Months.

Do I need a prescription ?

(ARTG)

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more

• 1 vial per pack pack

Pregnant or planning a pregnancy ?

(AHT)

For the active ingredient nivolumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.